NEWS: We recently announced a licensing agreement with Ichnos Glenmark Innovation (IGI) for a trispecific antibody currently in development for #MultipleMyeloma. This agreement reinforces our commitment to advance novel therapies, including multispecific antibodies for people living with #cancer. Learn more here: https://xmrrwallet.com/cmx.pbit.ly/44APaa0 [Video description: On-screen text reads, "Oncology News."]
Congratulations
Admirable for the Innovation!
Congratulations 🎊
。
Hello, This is Haruka from China. Can you give me contact informatioan of Africa sale manager? There is an order.
ABBVIE proud!!
Multiple Myeloma has been a personal journey !! So proud of ABBVIE !!
Amazing innovation!!
AbbVie is entering the hematologic malignancy space with a brilliant concept and promising data: a first-in-class CD38×BCMA×CD3 trispecific antibody. Here’s my breakdown of how this approach could advance deep B-cell depletion strategies: -Dual targeting of CD38 and BCMA, two highly expressed but non-overlapping markers on malignant and mature plasma cells, enables the capture of heterogeneous tumor populations—including CD38-high/BCMA-low and BCMA-high/CD38-low cells. -Reduces risk of antigen escape, a common challenge with monotherapies like BCMA CAR-T or daratumumab (anti-CD38). -Overcomes resistance mechanisms arising from BCMA loss or CD38 downregulation after therapies like daratumumab or isatuximab. -Facilitates broad and deep depletion across early, mature, and malignant B/plasma cell compartments. -Potent T-Cell Activation via CD3 arm I’m particularly curious to see comparative data versus current mono- and bispecific antibody therapies such as daratumumab, isatuximab, elranatamab, teclistamab, alnuctamab, and linvoseltamab (Lynyzfic). This could be a major step forward in reshaping the multiple myeloma treatment landscape.
This licensing agreement between Ichnos Glenmark Innovation and the involved parties marks a significant milestone in advancing trispecific antibody therapies for Multiple Myeloma. Such collaborative efforts are essential to propel innovative and effective treatment options for individuals battling cancer. The commitment to developing multispecific antibodies highlights the continuous dedication to transforming oncology care and improving patient outcomes. 🌟🔬🎗 For More, visit our page: marketaccesstoday.com #BiotechProgress #CancerResearch #MultipleMyeloma #OncologyInnovation #MarketAccess #MarketAccessToday